Angiotensin Receptor Neprilysin Inhibition and Associated Outcomes by Race and Ethnicity in Patients With Heart Failure With Reduced Ejection Fraction: Data From CHAMP-HF

• Published in: Journal of the American Heart Association Vol. 11; no. 12; p. e022889
• Main Authors: Chapman, Brittany, Hellkamp, Anne S, Thomas, Laine E, Albert, Nancy M, Butler, Javed, Patterson, J Herbert, Hernandez, Adrian F, Williams, Fredonia B, Shen, Xian, Spertus, John A, Fonarow, Gregg C, DeVore, Adam D
• Format: Journal Article
• Language: English
• Published: England John Wiley and Sons Inc 21.06.2022; Wiley
• Subjects: angiotensin receptor neprilysin inhibitor; heart failure; Original Research; population groups; registries; sacubitril/valsartan; heart failure; population groups; registries; angiotensin receptor neprilysin inhibitor; sacubitril/valsartan
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.121.022889

Background There are limited data on the use of angiotensin receptor neprilysin inhibitors (ARNIs) in minority populations with heart failure (HF) with reduced ejection fraction. We used data from the CHAMP-HF (Change the Management of Patients With Heart Failure) registry to evaluate ARNI initiation and associated changes in health status and clinical outcomes across different races and ethnicities. Methods and Results CHAMP-HF was a prospective, observational registry of US outpatients with chronic HF with reduced ejection fraction. We compared patients starting ARNI with patients not starting ARNI using a propensity-matched analysis. Patients were grouped as Hispanic, non-Hispanic Black, non-Hispanic White, or non-Hispanic other individuals, where "non-Hispanic other" consists of all patients who did not identify as Hispanic, Black, or White. Health status was assessed using the 12-item Kansas City Cardiomyopathy Questionnaire. Outcomes were analyzed with multivariable models that included race and ethnicity, ARNI initiation, and an interaction term between race and ethnicity and ARNI initiation. Cox proportional hazards models were used for death/HF hospitalization, and multiple regression was used for change in Kansas City Cardiomyopathy Questionnaire score. The analysis included 1516 patients, with 758 patients in each group (ARNI and no ARNI). Changes in Kansas City Cardiomyopathy Questionnaire score after ARNI initiation were similar among all race and ethnicity groups (mean [SD], non-Hispanic White individuals, 3.5 [19.0]; non-Hispanic Black individuals, 2.0 [17.0]; non-Hispanic other individuals, 5.5 [20.3]; and Hispanic individuals, 3.2 [20.1]), with no statistically significant interaction between race and ethnicity and ARNI initiation ( =0.21). There was similarly no statistically significant interaction between race and ethnicity and ARNI initiation for HF hospitalization ( =0.82) or all-cause mortality ( =0.92). Conclusions In a large registry of outpatients with HF with reduced ejection fraction, the association between ARNI initiation and outcomes did not differ by race and ethnicity. These data support the use of ARNI therapy for chronic HF with reduced ejection fraction irrespective of race and ethnicity.